secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2021-09-28T23:59:59+00:00
Accession:  0001193125-21-284839
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared
--------------------------------------------------------------------------------

- Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.
- No discontinuations due to adverse events; side effects mild-to-moderate, no dose titration needed.
- FDA cleared IND for NASH; 12-week NAFLD liver fat trial to start soon.
- Phase 2 obesity trial (48-week) planned for H1 2022; diabetes trial expected Q4 2021.
- Favorable trends in blood pressure, lipids, HOMA-IR; ketone bodies rise supports glucagon mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/0001193125-21-284839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/d200964d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-284839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer